Results 181 to 190 of about 496,064 (344)
Ketogenic diet for infantile epileptic spasms
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury +3 more
wiley +1 more source
Unequal gains: evaluating Alabama's infant mortality reduction initiative by race and marital status. [PDF]
Malak N, Horan H, Albright DL.
europepmc +1 more source
Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention
ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou +5 more
wiley +1 more source
Stiripentol use in Dravet syndrome patients in the USA: Results of a real‐world study
Abstract Objective Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with a high seizure burden and mortality risk. Stiripentol, one of the first DS‐specific therapies, received FDA approval in 2018 but its real‐world use and impact post‐approval in the USA remain insufficiently characterized.
Elaine Wirrell +11 more
wiley +1 more source
Infant mortality rates in Ghana: progress toward sustainable development goal 3. [PDF]
Opoku S, Adama ZK, Abuga S.
europepmc +1 more source
Abstract Objectives Infantile epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy of infantile onset. While epidemiological data from Western countries and global estimates are available, consolidated evidence on the burden of IESS in India remains limited.
Akanksha Singh +6 more
wiley +1 more source
Income Inequality and Infant Mortality in New York City [PDF]
Nancy Sohler
openalex +1 more source
Abstract Objective Dravet syndrome (DS) is a rare disease with a high clinical and socioeconomic impact on patients, society, and the healthcare system. The recent approval of therapies such as fenfluramine (FFA) has transformed the treatment landscape; however, data on their cost‐effectiveness are still scarce. This study evaluates the real‐world cost‐
Paolo A. Cortesi +15 more
wiley +1 more source
Pre-pregnancy and gestational cardiometabolic disorders and risk of preterm birth and infant mortality. [PDF]
Cheng Y +6 more
europepmc +1 more source

